Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie’s disease: a case-control study

References

• SchwarzerUSommerFKlotzTBraunMReifenrathBEngelmannUThe prevalence of Peyronie’s disease: results of a large surveyBJU Int20018872773011890244
   PubMed Web of Science ®Google Scholar
• MulhallJPCreechSDBoorjianSASubjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screeningJ Urol20041712350235315126819
   PubMed Web of Science ®Google Scholar
• DibenedettiDBNguyenDZografosLZiemieckiRZhouXAPopulation-based study of Peyronie’s disease: prevalence and treatment patterns in the United StatesAdv Urol2011201128250310.1155/2011/282503 Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202120/pdf/AU2011-282503.pdfAccessed November 18, 201522110491
   PubMedGoogle Scholar
• YafiFAPinskyMRSangkumPHellstromWJTherapeutic advances in the treatment of Peyronie’s diseaseAndrology20153465066026097120
   PubMed Web of Science ®Google Scholar
• WildSRoglicGGreenASicreeRKingHGlobal prevalence of diabetes: estimates for the year 2000 and projections for 2030Diabetes Care20042751047105315111519
   PubMed Web of Science ®Google Scholar
• TefekliAKandiraliEErolHAlpTKöksalTKadioğluAPeyronie’s disease in men under age 40: characteristics and outcomeInt J Impot Res2001131182311313836
   PubMed Web of Science ®Google Scholar
• LevineLAEstradaCRStormDWMatkovTGPeyronie disease in younger men: characteristics and treatment resultsJ Androl2003241273212514077
   PubMedGoogle Scholar
• PaulisGCavalliniGBarlettaDTurchiPVitarelliAFabianiAClinical and epidemiological characteristics of young patients with Peyronie’s disease: a retrospective studyRes Rep Urol20159710711126185748
   PubMedGoogle Scholar
• DevineCJJrSomersKDJordanGHSchlossbergSMProposal: trauma as the cause of the Peyronie’s lesionJ Urol19971572852908976281
   PubMed Web of Science ®Google Scholar
• JarowJPLoweFCPenile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunctionJ Urol1997158138813909302127
   PubMed Web of Science ®Google Scholar
• ZargooshiJTrauma as the cause of Peyronie’s disease: penile fracture as a model of traumaJ Urol200417218618815201768
   PubMed Web of Science ®Google Scholar
• RompelRWeidnerWMueller-EckhardtGHLA association of idiopathic Peyronie’s disease: an indication of autoimmune phenomena in etiopathogenesis?Tissue Antigens19913831041061796451
   PubMed Web of Science ®Google Scholar
• DolmansGHWerkerPMde JongIJNijmanRJLifeLines Cohort StudyWijmengaCOphoffRAWNT2 locus is involved in genetic susceptibility of Peyronie’s diseaseJ Sex Med2012951430143422489561
   PubMed Web of Science ®Google Scholar
• DiegelmannRFCellular and biochemical aspects of normal and abnormal wound healing: an overviewJ Urol19971572983028976284
   PubMed Web of Science ®Google Scholar
• SomersKDDawsonDMFibrin deposition in Peyronie’s disease plaqueJ Urol19971573113158976287
   PubMed Web of Science ®Google Scholar
• Van de WaterLMechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie’s diseaseJ Urol19971573063108976286
   PubMed Web of Science ®Google Scholar
• Gonzalez-CadavidNFMechanisms of penile fibrosisJ Sex Med20096Suppl 335336219267860
   PubMed Web of Science ®Google Scholar
• PaulisGBrancatoTInflammatory mechanisms and oxidative stress in Peyronie’s disease. Therapeutic “rationale” and related emerging treatment strategiesInflamm Allergy Drug Targets201211485722309083
   PubMedGoogle Scholar
• DavilaHHMageeTRVernetDRajferJGonzalez-CadavidNFGene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie’s diseaseBiol Reprod20047151568157715240426
   PubMed Web of Science ®Google Scholar
• Gonzalez-CadavidNFMageeTRFerriniMQianAVernetDRajferJGene expression in Peyronie’s diseaseInt J Impot Res200214536137412454687
   PubMed Web of Science ®Google Scholar
• El-SakkaAIHassobaHMPillarisettyRJDahiyaRLueTFPeyronie’s disease is associated with an increase in transforming growth factor-beta protein expressionJ Urol19971584139113949302128
   PubMed Web of Science ®Google Scholar
• ZimmermannRPFeilGBockCHoeltlLStenzlASignificant alterations of serum cytokine levels in patients with Peyronie’s diseaseInt Braz J Urol200834445746618778497
   PubMed Web of Science ®Google Scholar
• SikkaSCHellstromWJGRole of oxidative stress and antioxidants in Peyronie’s diseaseInt J Impot Res20021435336012454686
   PubMed Web of Science ®Google Scholar
• BichlerKHLahmeSMattauchWPetriECollagen metabolism in induratio penis plastica (IPP)Urologe A19983733063119646430
   PubMedGoogle Scholar
• MageeTRQianARajferJSanderFCLevineLAGonzalez-CadavidNFGene expression profiles in the Peyronie’s disease plaqueUrology200259345145711880101
   PubMed Web of Science ®Google Scholar
• HauckEWDiemerTSchmelzHUWeidnerWA critical analysis of nonsurgical treatment of Peyronie’s diseaseEur Urol20064998799716698449
   PubMed Web of Science ®Google Scholar
• LevineLAEstradaCRIntralesional verapamil for the treatment of Peyronie’s disease: a reviewInt J Impot Res200214532432812454681
   PubMed Web of Science ®Google Scholar
• CavalliniGBiagiottiGKoverechAVitaliGOral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie’s diseaseBJU Int200289989590012010235
   PubMed Web of Science ®Google Scholar
• GelbardMGoldsteinIHellstromWJClinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studiesJ Urol2013190119920723376148
   PubMed Web of Science ®Google Scholar
• SafarinejadMRHosseiniSYKolahiAAComparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie’s disease: a double-blind, placebo controlled, randomized studyJ Urol20071781398140317706714
   PubMed Web of Science ®Google Scholar
• BrantWODeanRCLueTFTreatment of Peyronie’s disease with oral pentoxifyllineNat Clin Pract Urol20063211111516470210
   PubMedGoogle Scholar
• AlizadehMKarimiFFallahMREvaluation of verapamil efficacy in Peyronie’s disease comparing with pentoxifyllineGlob J Health Sci201467 Spec233025363175
   PubMedGoogle Scholar
• PaulisGPirozzi FarinaFCavalliniGPentoxifylline associated with other antioxidants (multimodal therapy) on patients with Peyronie’s disease. Results of a controlled studyAndrology (Los Angel)2014312310.4172/2167-0250.1000123
   Google Scholar
• PalmieriAImbimboCCretaMVerzePFuscoFMironeVTadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trialInt J Androl201235219019522085227
   PubMed Web of Science ®Google Scholar
• PavoneCNapoliGCaruanaGAlongeVUsalaMAbbadessaDSafety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie’s disease: a phase I studyBJU Int2012110111712122176734
   PubMed Web of Science ®Google Scholar
• PavoneCCastrianniDRomeoSTECAR therapy for Peyronie’s disease: a phase-one prospective study. Great evidence in patients with erectile dysfunctionUrologia201380214815323423676
   PubMedGoogle Scholar
• GennaroRBarlettaDPaulisGIntralesional hyaluronic acid: an innovative treatment for Peyronie’s diseaseInt Urol Nephrol201547101595160210.1007/s11255-015-1074-126257044
   PubMed Web of Science ®Google Scholar
• PaulisGD’AscenzoRNupieriPEffectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie’s disease: a study of 151 casesInt J Androl201235452152721950543
   PubMedGoogle Scholar
• PaulisGCavalliniGGiorgioGDQuattrocchiSBrancatoTAlvaroRLong-term multimodal therapy (verapamil associated with propolis, blueberry, vitamin E and local diclofenac) on patients with Peyronie’s disease (chronic inflammation of the tunica albuginea). Results of a controlled studyInflamm Allergy Drug Targets201312640340924304332
   PubMedGoogle Scholar
• FitchWP3rdEasterlingWJTalbertRLBordovskyMJMosierMTopical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie’s disease – a placebo-controlled pilot studyJ Sex Med20074247748417367443
   PubMed Web of Science ®Google Scholar
• RiedlCRSternigPGalléGLiposomal recombinant human superoxide dismutase for the treatment of Peyronie’s disease: a randomized placebo-controlled double-blind prospective clinical studyEur Urol200548465666115982798
   PubMed Web of Science ®Google Scholar
• PaulisGBrancatoTD’AscenzoREfficacy of vitamin E in the conservative treatment of Peyronie’s disease: legend or reality? A controlled study of 70 casesAndrology2013112012823258640
   PubMed Web of Science ®Google Scholar
• Martínez-SalamancaJIEguiAMoncadaIAcute phase Peyronie’s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlationJ Sex Med201411250651524261900
   PubMed Web of Science ®Google Scholar
• RaheemAAGaraffaGRaheemTAThe role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s diseaseBJU Int201010681178118020438558
   PubMed Web of Science ®Google Scholar
• LinGShindelAWBanieLPentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1J Sex Med2010751787179720384945
   PubMed Web of Science ®Google Scholar
• ShindelAWLinGNingHPentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrixJ Sex Med2010762077208520367772
   PubMed Web of Science ®Google Scholar
• BermanBDuncanMRPentoxifylline inhibits normal human dermal fibroblast in vitroproliferation, collagen, glycosaminoglycan, and fibronectin production, and increases collagenase activityJ Invest Dermatol19899246056102539414
   PubMed Web of Science ®Google Scholar
• BermanBDuncanMRPentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphoea skin and their production of collagen, glycosaminoglycans and fibronectinBr J Dermatol199012333393462206972
   PubMed Web of Science ®Google Scholar
• KelâmiAAutophotography in evaluation of functional penile disordersUrology1983216286296868238
   PubMed Web of Science ®Google Scholar
• RosenRCRileyAWagnerGOsterlohIHKirkpatrickJMishrsAThe international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunctionUrology1997498228309187685
   PubMed Web of Science ®Google Scholar
• FarrarJTYoungJPJrLaMoreauxLWerthJLPooleRMClinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scalePain20019414915811690728
   PubMed Web of Science ®Google Scholar
• PrandoDNew sonographic aspects of peyronie diseaseJ Ultrasound Med20092821723219168771
   PubMed Web of Science ®Google Scholar
• BehreHMZitzmannMImaging diagnosticsNieschlagEBehreHMNieschlagSAndrology: Male Reproductive Health and DysfunctionBerlinSpringer-Verlag2010101108
   Google Scholar
• KimCKChoJYProstateKimSHRadiology Illustrated: UroradiologyBerlinSpringer-Verlag2012826
   Google Scholar
• EhrlyAMImprovement of the flow properties of blood: a new therapeutical approach in occlusive arterial diseaseAngiology19762731881961078314
   PubMed Web of Science ®Google Scholar
• KellnerHTreatment of chronic arterial circulatory disorders. Double blind trial with Trental 400MMW Munch Med Wochenschr19761184313991402825745
   PubMedGoogle Scholar
• TahaHGrochot-PrzeczekAWasHModulation of inflammatory response by pentoxifylline is independent of heme oxygenase-1 pathwayJ Physiol Pharmacol200960231219617639
   PubMed Web of Science ®Google Scholar
• ShamsaraJBehravanJFalsoleimanHMohammadpourAHRamezaniMThe effects of pentoxifylline administration on NFKB P50 transcription factor expressionARYA Atheroscler20127413313723205044
   PubMedGoogle Scholar
• González-EspinozaLRojas-CamposEMedina-PérezMPeña-QuinteroPGómez-NavarroBCueto-ManzanoAMPentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trialNephrol Dial Transplant20122752023202821968012
   PubMed Web of Science ®Google Scholar
• TsutsumimotoTWakabayashiSKinoshitaTHoriuchiHTakaokaKA phosphodiesterase inhibitor, pentoxifylline, enhances the bone morphogenetic protein-4 (BMP-4)-dependent differentiation of osteoprogenitor cellsBone200231339640112231412
   PubMed Web of Science ®Google Scholar
• DereeJMartinsJOMelbostadHLoomisWHCoimbraRInsights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibitionClinics (Sao Paulo)200863332132818568240
   PubMed Web of Science ®Google Scholar
• ValenteEGVernetDFerriniMGQianARajferJGonzalez-CadavidNFL-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast culturesNitric Oxide20039422924414996430
   PubMed Web of Science ®Google Scholar
• SmithJFShindelAWHuangYCPentoxifylline treatment and penile calcifications in men with Peyronie’s diseaseAsian J Androl201113232232521102473
   PubMed Web of Science ®Google Scholar
• AbernMRLarsenSLevineLACombination of penile traction, intralesional verapamil, and oral therapies for Peyronie’s diseaseJ Sex Med20129128829522024053
   PubMed Web of Science ®Google Scholar
• CiociolaFColpiGMPeyronie’s disease: a “triple oxygenant therapy”Arch Ital Urol Androl2013851364023695404
   PubMedGoogle Scholar
• Dell’AttiLUghiGEfficacy of pentoxifylline in Peyronie’s disease: clinical case of a young manArch Ital Urol Androl201486323723825308598
   PubMedGoogle Scholar
• O’LearyKAde Pascual-TeresaSNeedsPWBaoYPO’BrienNMWilliamsonGEffect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcriptionMutat Res20045511–224525415225597
   PubMed Web of Science ®Google Scholar
• ParolaMMuracaRDianzaniIVitamin E dietary supplementation inhibits transforming growth factor beta 1 gene expression in the rat liverFEBS Lett199230832672701505665
   PubMed Web of Science ®Google Scholar
• AlcaláMSánchez-VeraISevillanoJVitamin E reduces adipose tissue fibrosis, inflammation, and oxidative stress and improves metabolic profile in obesityObesity (Silver Spring)20152381598160626148343
   PubMed Web of Science ®Google Scholar
• MárquezNSanchoRMachoACalzadoMAFiebichBLMuñozECaffeic acid phenethyl ester inhibits T-cell activation by targeting both nuclear factor of activated T-cells and NF-kappaB transcription factorsJ Pharmacol Exp Ther20043083993100114617683
   PubMed Web of Science ®Google Scholar
• de las HerasBHortelanoSMolecular basis of the anti-inflammatory effects of terpenoidsInflamm Allergy Drug Targets20098283919275691
   PubMedGoogle Scholar
• WangQXiaMLiuCCyanidin-3-O-beta-glucoside inhibits iNOS and COX-2 expression by inducing liver X receptor alpha activation in THP-1 macrophagesLife Sci2008835–617618418619979
   PubMed Web of Science ®Google Scholar
• MulhallJPThomJLubranoTShankeyTVBasic fibroblast growth factor expression in Peyronie’s diseaseJ Urol2001165241942311176387
   PubMed Web of Science ®Google Scholar
• GentileVModestiALa PeraGUltrastructural and immunohistochemical characterization of the tunica albuginea in Peyronie’s disease and veno-occlusive dysfunctionJ Androl1996172961038723432
   PubMedGoogle Scholar
• Gouni-BertholdISachinidisAMolecular mechanisms explaining the preventive effects of catechins on the development of proliferative diseasesCurr Pharm Des200410111261127115078140
   PubMed Web of Science ®Google Scholar
• TakaiSMatsushima-NishiwakiRAdachiS(−)-Epigallocatechin gallate reduces platelet-derived growth factor-BB-stimulated interleukin-6 synthesis in osteoblasts: suppression of SAPK/JNKMediators Inflamm2008200829180810.1155/2008/29180819148296
   PubMed Web of Science ®Google Scholar
• EscolarDMZimmermanABertoriniTPentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trialNeurology2012781290491322402864
   PubMed Web of Science ®Google Scholar
• TianMLShenYSunZLZhaYEfficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysisInt Urol Nephrol201547581582225862237
   PubMed Web of Science ®Google Scholar
• HellstromWJMedical management of Peyronie’s diseaseJ Androl200930439740518974422
   PubMedGoogle Scholar
• MulhallJPSchiffJGuhringPAn analysis of the natural history of Peyronie’s diseaseJ Urol20061752115211816697815
   PubMed Web of Science ®Google Scholar
• LamprakopoulosAZorzosILykourinasMThe use of betamethasone and yaluronidase injections in the treatment of Peyronie’s diseaseScand J Urol Nephrol200034635536011195899
   PubMed Web of Science ®Google Scholar
• Prieto CastroRMLeva VallejoMERegueiro LopezJCAnglada CuradoFJAlvarez KindelanJRequena TapiaMJCombined treatment with vitamin E and colchicine in the early stages of Peyronie’s diseaseBJU Int200391652252412656907
   PubMed Web of Science ®Google Scholar
• Candebat MonteroLHMiranda ReyesPLDíaz GarcíaFGonzález FerroIBarbosa RamosFCodorniu FuretJPeyronie’s disease: treatment with interferon and laserArch Esp Urol200861341342318581679
   PubMedGoogle Scholar
• TaylorFLLevineLANon-surgical therapy of Peyronie’s diseaseAsian J Androl2008101798718087647
   PubMed Web of Science ®Google Scholar
• KuehhasFEWeiblPGeorgiTDjakovicNHerwigRPeyronie’s disease: nonsurgical therapy optionsRev Urol201113313914622110397
   PubMedGoogle Scholar
• LarsenSMLevineLAReview of non-surgical treatment options for Peyronie’s diseaseInt J Impot Res201224111021918530
   PubMed Web of Science ®Google Scholar
• HalalAAGeavletePCebanEPharmacological therapy in patients diagnosed with Peyronie’s diseaseJ Med Life20125219219522802890
   PubMedGoogle Scholar
• LevineLAPeyronie’s disease: contemporary review of non-surgical treatmentTranslational Androl Urol201321 Available from: http://www.amepc.org/tau/article/view/1461Accessed November 18, 2015
   Google Scholar
• FavillaVRussoGIPriviteraSCombination of intralesional verapamil and oral antioxidants for Peyronie’s disease: a prospective, randomised controlled studyAndrologia201446893694224124921
   PubMed Web of Science ®Google Scholar
• PaulisGCombination therapy (in the treatment of Peyronie’s disease)CavalliniGPaulisGPeyronie’s Disease. A Comprehensive GuideSwitzerlandSpringer International Publishing201597105
   Google Scholar